Takeda Hits Accelerator On TAK-861 After Phase II Narcolepsy Win
Executive Summary
The drug maker plans to move the drug into Phase III development for NT1, though it appears to have missed on NT2. But a lack of key toxicities may bode well for the orexin agonist class too.